Inflammasome activation and the progression of inflammatory bowel disease are modulated by palmitoylation of NLRP3, while inflammasome activation and the severity of dextran sulfate sodium (DSS)-induced colitis in mice are effectively attenuated by pharmacological inhibition of NLRP3 palmitoylation (20). This evidence concerns the gene NLRP3 and inflammatory bowel disease.